Puma Biotechnology Inc  

(Public, NASDAQ:PBYI)   Watch this stock  
Find more results for PBYI
-1.05 (-1.54%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 66.20 - 69.05
52 week 28.35 - 136.90
Open 67.55
Vol / Avg. 509,765.00/1.17M
Mkt cap 2.48B
P/E     -
Div/yield     -
EPS -8.19
Shares 37.53M
Beta 0.18
Inst. own 98%
Mar 13, 2018
Puma Biotechnology Inc at Cowen Health care Conference - 11:20AM EDT - Add to calendar
Mar 1, 2018
Q4 2017 Puma Biotechnology Inc Earnings Call - 4:30PM EST - Add to calendar
Mar 1, 2018
Q4 2017 Puma Biotechnology Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 14, 2018
Puma Biotechnology Inc at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1270.04% -
Operating margin -1274.31% -
EBITD margin - -
Return on average assets -174.56% -112.06%
Return on average equity -310.69% -132.75%
Employees 308 -
CDP Score - -


10880 Wilshire Blvd Ste 2150
LOS ANGELES, CA 90024-4106
United States - Map
+1-424-2486500 (Phone)
+1-424-2486501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Officers and directors

Alan H. Auerbach Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Charles R. Eyler Senior Vice President - Finance and Administration, Treasurer
Age: 69
Bio & Compensation  - Reuters
Richard P. Bryce Chief Scientific Officer, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Steven Lo Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Jay M. Moyes Independent Director
Age: 63
Bio & Compensation  - Reuters
Adrian M Senderowicz Independent Director
Age: 53
Bio & Compensation  - Reuters
Troy E. Wilson Ph.D. J.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Frank E. Zavrl Independent Director
Age: 51
Bio & Compensation  - Reuters